International forum of allergy & rhinology · 2026
Microbial-Metabolite Signatures Are Associated With Glucocorticoid Responsiveness in Chronic Rhinosinusitis With Nasal Polyps.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Ying-Ying, Ding Xin-Yu, Lu Mei-Ping, Chen Yan-Bing, Yuan Ye, Jiang Lin, Zhang Min, Cheng Lei
Аннотация
BACKGROUND: Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) exhibit heterogeneous responses to oral glucocorticoids (GCs), but the biological basis of this variability remains unclear.
OBJECTIVE: To identify gut microbiome‒plasma metabolomic signatures associated with GC responsiveness in CRSwNP patients and to compare their predictive value with that of conventional clinical indicators.
METHODS: Patients with CRSwNP aged 18-65 years with bilateral nasal polyps and a nasal polyp score (NPS) ≥ 2 on at least one side were enrolled, together with septoplasty controls without sinonasal disease. GC responsiveness was defined as the change in endoscopic NPS after 2 weeks of oral methylprednisolone. Fecal shotgun metagenomic and untargeted plasma metabolomics were performed.
RESULTS: Twenty-six CRSwNP patients and 30 controls were included. At baseline, GC responders had significantly greater tissue eosinophilic inflammation, whereas GC non-responders had higher NPS. Responders exhibited distinct baseline gut microbial and plasma metabolic profiles, characterized by the enrichment of Bacteroides caccae, Microbacterium flavum, and Mucilaginibacter rigui, and markedly elevated levels of lupinisoflavone N, CAY10622, kanzonol V, and D-sorbitol. These baseline features were positively correlated with tissue eosinophilic inflammation. After treatment, reductions in Lund-Mackay CT total score, ethmoid/maxillary sinus CT score ratio, NPS, tissue eosinophilic inflammation, and tissue IL-6 mRNA levels were significantly greater in GC responders. Tissue eosinophil count was the strongest conventional predictor (AUC = 0.885), while the integrated multiomics model achieved an AUC of 0.899, showing only marginal improvement.
CONCLUSION: Gut microbiome-plasma metabolomic signatures capture the systemic immunometabolic context of GC therapy and are linked to GC responsiveness in CRSwNP, explaining interindividual treatment efficacy differences.
OBJECTIVE: To identify gut microbiome‒plasma metabolomic signatures associated with GC responsiveness in CRSwNP patients and to compare their predictive value with that of conventional clinical indicators.
METHODS: Patients with CRSwNP aged 18-65 years with bilateral nasal polyps and a nasal polyp score (NPS) ≥ 2 on at least one side were enrolled, together with septoplasty controls without sinonasal disease. GC responsiveness was defined as the change in endoscopic NPS after 2 weeks of oral methylprednisolone. Fecal shotgun metagenomic and untargeted plasma metabolomics were performed.
RESULTS: Twenty-six CRSwNP patients and 30 controls were included. At baseline, GC responders had significantly greater tissue eosinophilic inflammation, whereas GC non-responders had higher NPS. Responders exhibited distinct baseline gut microbial and plasma metabolic profiles, characterized by the enrichment of Bacteroides caccae, Microbacterium flavum, and Mucilaginibacter rigui, and markedly elevated levels of lupinisoflavone N, CAY10622, kanzonol V, and D-sorbitol. These baseline features were positively correlated with tissue eosinophilic inflammation. After treatment, reductions in Lund-Mackay CT total score, ethmoid/maxillary sinus CT score ratio, NPS, tissue eosinophilic inflammation, and tissue IL-6 mRNA levels were significantly greater in GC responders. Tissue eosinophil count was the strongest conventional predictor (AUC = 0.885), while the integrated multiomics model achieved an AUC of 0.899, showing only marginal improvement.
CONCLUSION: Gut microbiome-plasma metabolomic signatures capture the systemic immunometabolic context of GC therapy and are linked to GC responsiveness in CRSwNP, explaining interindividual treatment efficacy differences.